ERBB2 and breast carcinoma: Another strategy developed to inhibit EGFR is the usage of monoclonal antibodies such as trastuzumab and cetuximab, which can control the growth of breast cancer cells overexpressing human epidermal growth factor receptor 2 (HER2).